Psoriasis Market Size in the 7MM is Estimated to Exceed USD 38.4 Billion by 2035

The psoriasis market reached a value of USD 20.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 38.4 Billion by 2035, exhibiting a growth rate (CAGR) of 5.96% during 2025-2035.

The psoriasis market is showing solid growth trends. Therapeutic advancements, increasing patient understanding, and increasing prevalence contribute to growth in the market. Psoriasis is a chronic autoimmune disease of the skin that causes red, scaly patches in areas of the body, such as the scalp and elbows. It affects millions of people, resulting in high levels of pain, discomfort, and stress.

The growth of the market is largely attributed to the development and growth of biologic therapies. With their targeted approaches, biologics have changed the way patients with psoriasis are treated, offering a safer and more efficacious option than previous systemic therapies. Biologics, including interleukin inhibitors, have become the preferred approach for treating moderate to severe psoriasis, introducing significant growth in the market.

Request for a sample of this report: https://www.imarcgroup.com/psoriasis-market/requestsample

Biosimilars are also a relatively new product, which are biologic products that are highly similar to already approved biologic therapies, and increase access and affordability for patients, especially in novel economies. This is especially important to limit the treatment gap in countries with little-to-no mitigation options to healthcare.

The increasing rates of psoriasis cases are a significant market driver. The increased incidence is driven by the combination of genetic predisposition, environmental triggers, lifestyle changes, and more effective diagnostic tools and expanded pathways to diagnosis. These factors have contributed to diagnoses being made earlier in the disease recognition process, allowing patients to access treatments much earlier, and increasing the number of patients who will utilize treatment and obtain routine medical care.

The market is also being driven by patient support and education programs, allowing patients to access early visits with physicians and comply with treatment protocols to help better manage their disease and overall quality of life.

Technology developments in telemedicine, digital health platforms, and other products will alter patient engagement and monitoring of disease. With advancements being made through technology, remote consultations, monitoring of treatments, and individualized care plans for patients living with psoriasis will be enhanced so that psoriasis treatment becomes simpler, easier, and less time-consuming.

Ask the Analyst for Customization and Get Full Insights with TOC: https://www.imarcgroup.com/request?type=report&id=7295&flag=E

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the psoriasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the psoriasis market
Reimbursement scenario in the market
In-market and pipeline drugs

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

This report also provides a detailed analysis of the current psoriasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape With Key Players:

The competitive landscape of the psoriasis market has been studied in the report with the detailed profiles of the key players operating in the market.

Ortho Dermatologics
Sun Pharmaceutical Industries, Inc.
Arcutis Biotherapeutics, Inc.
Amgen Inc.
Alumis Inc.
Soligenix
SFA Therapeutics, Inc.
Dermavant Sciences, Inc.

IMARC Group Offers Other Reports:

Subdural Haematoma Market https://www.imarcgroup.com/subdural-haematoma-market

Ankylosing Spondylitis Market https://www.imarcgroup.com/ankylosing-spondylitis-market

Diffuse Large B-cell Lymphoma (DLBCL) Market https://www.imarcgroup.com/diffuse-large-b-cell-lymphoma-market

Non Hodgkin's Lymphoma Market https://www.imarcgroup.com/non-hodgkins-lymphoma-market

Immune Thrombocytopenia (ITP) Market https://www.imarcgroup.com/immune-thrombocytopenia-market

Contact US:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145

About Us:

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.

IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

This release was published on openPR.